CRISPR Therapeutics AG (0VRQ.L)

56,83 +1,64 (+2,97%) Börsenschluss: 07:05PM BST

CRISPR Therapeutics AG

Baarerstrasse 14
Zug 6300
Switzerland
41 41 561 32 77
https://www.crisprtx.com

Sektor(en): 
Branche: 
Vollzeitmitarbeiter: 407

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Samarth Kulkarni Ph.D.	CEO & Chairman	1,35M	4,06M	1978
Dr. Raju Yashaswi Prasad Ph.D.	Chief Financial Officer	880,1k	N/A	1984
Mr. James R. Kasinger	General Counsel & Secretary	734,72k	N/A	1972
Mr. Shaun Foy	Founder	N/A	N/A	N/A
Dr. Emmanuelle Marie Charpentier	Co-Founder & Scientific Advisory Board Member	N/A	N/A	N/A
Dr. Craig C. Mello Ph.D.	Scientific Founder & Advisory Board Member	N/A	N/A	N/A
Dr. Chad A. Cowan Ph.D.	Scientific Founder	N/A	N/A	N/A
Dr. Matthew Porteus M.D., Ph.D.	Scientific Founder & Advisory Board Member	N/A	N/A	1966
Dr. Daniel G. Anderson Ph.D.	Scientific Founder & Advisory Board Member	N/A	N/A	N/A
Mr. Stephen Kennedy	Head of Technical Operations	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease, and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmunune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and VCTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

Corporate Governance

CRISPR Therapeutics AGs ISS Governance QualityScore, Stand 1. Mai 2024, lautet 8. Die grundlegenden Scores sind Audit: 4, Vorstand: 9, Shareholderrechte: 2, Kompensation: 10.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.